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OBJECTIVES This study was designed to evaluate the potential benefit of screening previously irradiated
patients with echocardiography.
BACKGROUND Mediastinal irradiation is known to cause cardiac disease. However, the prevalence of
asymptomatic cardiac disease and the potential for intervention before symptom development
are unknown.
METHODS We recruited 294 asymptomatic patients (mean age 42  9 years, 49% men, mean mantle
irradiation dose 43  0.3 Gy) treated with at least 35 Gy to the mediastinum for Hodgkin’s
disease. After providing written consent, each patient underwent electrocardiography and
transthoracic echocardiography.
RESULTS Valvular disease was common and increased with time following irradiation. Patients who had
received irradiation more than 20 years before evaluation had significantly more mild or
greater aortic regurgitation (60% vs. 4%, p  0.0001), moderate or greater tricuspid
regurgitation (4% vs. 0%, p  0.06), and aortic stenosis (16% vs. 0%, p  0.0008) than those
who had received irradiation within 10 years. The number needed to screen to detect one
candidate for endocarditis prophylaxis was 13 (95% confidence interval [CI] 7 to 44) for
patients treated within 10 years and 1.6 (95% CI 1.3 to 1.9) for those treated at least 20 years
ago. Compared with the Framingham Heart Study population, mildly reduced left ventricular
fractional shortening (30%) was more common (36% vs. 3%), and age- and gender-adjusted
left ventricular mass was lower (90  27 g/m vs. 117 g/m) in irradiated patients.
CONCLUSIONS There is a high prevalence of asymptomatic heart disease in general, and aortic valvular
disease in particular, following mediastinal irradiation. Screening echocardiography should be
considered for patients with a history of mediastinal irradiation. (J Am Coll Cardiol 2003;
42:743–9) © 2003 by the American College of Cardiology Foundation
Mediastinal irradiation is known to lead to symptomatic
cardiac disease such as constrictive pericarditis (1), aortic
and mitral valvular regurgitation (2), conduction defects (3),
and coronary artery disease (4,5). Because of the high cure
rate that is now possible with mediastinal irradiation, many
patients with Hodgkin’s disease are surviving for long
periods (6) and are at risk for irradiation-induced cardiac
diseases. The prevalence of preclinical cardiac disease is
largely unknown and may be substantial.
See page 750
The appropriate management of asymptomatic patients
with a history of mediastinal irradiation is unclear. If
asymptomatic cardiac disease is common following medias-
tinal irradiation, then periodic screening may be beneficial if
treatable conditions can be identified. For example, asymp-
tomatic patients with valvular disease may benefit from
endocarditis prophylaxis (7,8), whereas those with depressed
LV dysfunction may benefit from angiotensin-converting
enzyme inhibitors (9) or possibly beta-blockers (10).
To determine the potential benefit from screening
asymptomatic patients following mediastinal irradiation, we
addressed the following questions: What is the prevalence of
asymptomatic cardiac disease following mediastinal irradi-
ation? What patient- and treatment-related factors increase
the risk of radiation-induced heart disease?
METHODS
Patient population. Patients were eligible if they had
received at least 35 Gy of mantle irradiation for treatment
for Hodgkin’s disease, without symptomatic cardiac disease
(a history of pacemaker implant [n  1] was allowed), and
gave written consent to undergo noninvasive testing with
echocardiography and electrocardiography. The treatment
protocol included a LV block after 15 Gy, and a subcarinal
block that excluded most of the heart after 30 Gy. We
identified 335 eligible subjects by attempting to contact all
patients followed at Stanford Medical Center who were not
known to have died or known to have symptomatic disease.
Of these, 254 provided consent and were enrolled. An
additional 40 eligible patients treated elsewhere but meeting
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study criteria were included. Enrollment lasted from Octo-
ber 1994 through November 1998. The study protocol was
approved by the Human Research Committee at Stanford
University Medical Center.
Study protocol: noninvasive evaluation. AUSCULTATION
AND ELECTROCARDIOGRAPHY. Each patient underwent
resting 12-lead electrocardiography. Abnormalities in con-
duction, QRS and ST complexes and the presence of LV
hypertrophy were defined using Minnesota criteria (11).
A subset of 242 patients underwent cardiac auscultation
by their attending medical or radiation oncologist, who was
blind to the results of echocardiography. A group of 212 was
examined on the day of enrollment, and another 30 were
examined during the preceding 30 days. The presence of a
murmur and timing (systolic vs. diastolic) were recorded.
There was no significant difference in age, gender, dose of
radiation, or underlying valvular disease between those
undergoing and those not undergoing auscultation.
ECHOCARDIOGRAPHY. Each subject underwent two-
dimensional echocardiography, M-mode echocardiography,
color and pulsed Doppler studies of the aortic, mitral,
tricuspid, and pulmonary valves. All studies were performed
using commercially available ultrasound scanners (HP
Sonos 1500, 2500, Hewlett Packard, Mountain View,
California), and were recorded on 1⁄2-inch super VHS
videotape. Standard parasternal long-axis, short-axis, apical
four-chamber, and subcostal two-dimensional views were
obtained. M-mode measurements were obtained according
to the recommendations of the American Society of Echo-
cardiography (12). Cardiac volume measurements (from
M-mode) were standardized to height. Left ventricular
mass was calculated using the modified formula of Devereux
(13).
Regurgitation was assessed visually using definitions sim-
ilar to the Framingham Heart Study (14). Mitral and
tricuspid valvular regurgitation were graded using the ratio
of the color Doppler-jet area to the atrial area as a guide
(40% as severe, 20% to 40% as moderate, 20% but
extending at least 1 cm into the atrium as mild, and
extension 1 cm as trace). Regurgitation leading to reversal
in the hepatic or pulmonary veins was also considered
severe. Aortic and pulmonic regurgitation were visually
graded using the ratio of the width of the color jet to the
diameter of the outflow tract (50% as severe, 25% to 50%
as moderate, 10% to 24% as mild, and 10% as trace).
Aortic stenosis was considered present if the motion of the
aortic valve leaflets were restricted and the peak aortic
velocity was more than 2.0 m/s. Pericardial thickening and
regional wall motion abnormalities were graded using stan-
dard criteria (15,16). The echocardiographic studies were
interpreted by a single experienced echocardiographer who
was aware that the patient had received mediastinal irradi-
ation but was blind to the details of irradiation and to other
study data. The Food and Drug Administration’s classifi-
cation of valve disease was used to classify lesions into
significant (mild or greater aortic regurgitation, moderate or
greater mitral or tricuspid regurgitation, aortic stenosis) and
nonsignificant pathology (7). To directly compare our pop-
ulation from published population values from the Fra-
mingham Heart Study, we also classified valvular lesions as
trace, mild, and moderate or severe.
When available, we used published reports from the
Framingham Heart Study as a measure of the prevalence of
echocardiographic and electrocardiographic disease in the
general population. For Framingham data that were age-
and gender-specific, we adjusted the summary Framingham
value to match the age and gender distribution of our
population.
OUTCOME. We contacted patients at yearly intervals to
determine death or nonfatal cardiac events or new cardiac
diagnoses. Cardiac outcomes included a new diagnosis of
heart failure (HF), constrictive pericarditis, symptomatic
valvular disease, coronary artery disease (revascularization,
myocardial infarction [MI], unstable angina, stable angina),
and syncope.
STATISTICS. Patients were grouped based on the number of
years between irradiation and examination (2 to 10, 11 to 20
and 20) because initial analysis revealed a strong associa-
tion between time following irradiation and prevalence of
cardiac disease. Descriptive data are given as percentages
or means  SD. Comparisons of means were performed
using Student t test and analysis of variance. Differences in
proportions were performed using the chi-square test.
Multivariate analysis was performed using standard least-
squares regression if the dependent variable was continuous,
logistic regression if the dependent variable was categorical,
and proportional hazards if the outcome was event-free
survival. Multivariate models initially included the following
independent variables: age, gender, hypertension (yes/no),
diabetes (yes/no), chemotherapy (yes/no), biologically
equivalent irradiation dose (17), and time following irradi-
ation. Variables were removed from the model stepwise
until only those variables significantly associated (p  0.05)
with the dependent variable remained. Survival curves were
determined using Kaplan-Meier analysis. Differences be-
tween survival curves were evaluated using the log-rank
statistic. All analyses were performed using JMP (SAS
Institute, Cary, North Carolina) statistical software. A
two-tailed p value 0.05 was considered statistically signif-
icant.
Abbreviations and Acronyms
HF  heart failure
LV  left ventricular
MI  myocardial infarction
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RESULTS
The characteristics of the enrolled patients are listed in
Table 1. There were no significant differences in mean age
and gender distribution between the locally treated (n 
254) and referral populations (n 40); however, the referral
population had received slightly less mantle irradiation
(42 vs. 44 Gy, p  0.02). The patients ranged in age from
21 to 75 years and approximately half were men. A majority
of patients (59%) received 44 mantle Gy (range 35 to 70).
Time from irradiation to examination varied from 2 to 33
years.
Valvular disease. Valvular disease was several-fold more
common in irradiated patients than in the Framingham
population (14,18,19) (Table 2). This finding was most
striking for aortic regurgitation (Fig. 1), where the age- and
gender-adjusted risk was sevenfold higher for any aortic
regurgitation and 34-fold higher for moderate or greater
aortic regurgitation compared with the Framingham popu-
lation. Significant valve disease for which endocarditis
prophylaxis should be considered (mild or greater aortic
regurgitation, moderate or greater mitral or tricuspid regur-
gitation, aortic stenosis) was noted in 29% of irradiated
patients compared with 3% for an age- and gender-matched
Framingham cohort (14). The number needed to screen
with echocardiography to identify a candidate for endocar-
ditis prophylaxis decreased dramatically with time following
irradiation: 13 (95% confidence interval [CI] 7 to 44) for
patients at 2 to 10 years, four (3 to 6) for those at 11 to 20
years and 1.6 (1.3 to 1.9) for those more than 20 years
following irradiation.
The degree of valvular disease (thickening and regurgi-
tation) was related to time following irradiation (latency
period) for all valves, although the increase in disease over
time was greatest for the aortic valve (Table 2). For patients
irradiated within the past 10 years the prevalence of aortic
(13%) and mitral thickening (28%) was significantly less
(p  0.0001) than for those with irradiation more than 20
years before evaluation (aortic 61%, mitral 66%). The
Table 1. Patient Characteristics
Characteristic Value
Number 294
Age (yrs) 42  9
Male gender (%) 49
Hypertension (%) 9
Diabetes (%) 1
Thyroid replacement (%) 56
Time following irradiation (yrs) 15.0  7
Mean mantle irradiation dose (Gy) 43  0.3
Mean biologic equivalent dose* 71  7
Treatment with chemotherapy (%) 56
*For calculation of the biological equivalent dose (30).
Table 2. Valvular Disease Following Irradiation
Echocardiographic Finding
Years Following Irradiation
p Value*
General Population†
All Patients
n  294
2–10
n  89
11–20
n  132
>20
n  73 Prevalence (%) Source
Aortic regurgitation
Trace (%) 27 (9) 9 (10) 13 (10) 5 (7) 0.71 3.1 (14)
Mild (%) 62 (21) 3 (3.4) 26 (20) 33 (45)  0.0001 1.3 (14)
Moderate or severe (%) 15 (5.1) 1 (1.1) 3 (2.3) 11 (15)  0.0001 0.15 (14)
Mitral regurgitation
Trace (%) 87 (30) 27 (30) 44 (33) 16 (22) 0.21 75 (14)
Mild (%) 105 (36) 21 (24) 49 (37) 35 (48) 0.005 13 (14)
Moderate or severe (%) 10 (3.4) 2 (2.3) 5 (3.8) 3 (4.1) 0.71 0.54 (14)
Tricuspid regurgitation
Trace (%) 86 (29) 25 (28) 43 (33) 18 (25) 0.47 70 (14)
Mild (%) 43 (15) 8 (9) 19 (14) 16 (22) 0.07 13 (14)
Moderate or severe (%) 4 (1.4) 0 (0) 1 (0.8) 3 (4.1) 0.06 0.55 (14)
Pulmonic regurgitation‡
Trace (%) 106 (36) 37 (42) 45 (34) 24 (33) 0.40 17 (32)
Mild (%) 20 (7) 2 (2) 9 (7) 9 (12) 0.04  0.5 (32)
Moderate or severe (%) 0 (0) 0 (0) 0 (0) 0 (0) 1.0  0.5 (32)
Aortic stenosis (%) 13 (4) 0 (0) 1 (1) 12 (16) 0.008  0.5 (33)
*p for differences across groups based on time following irradiation. Percentages may not add up to 100 due to rounding; †Framingham data adjusted for age and gender to match
the irradiated cohort; ‡Pulmonic regurgitation could not be measured in two patients (group 2–10 years and group 11–20 years) due to poor image quality.
Figure 1. Prevalence of mild or greater aortic regurgitation stratified by age
and time following irradiation. The prevalence of aortic regurgitation
increases markedly with both age and time following irradiation. Open
bars  age 40 years; lined bars  age 40 to 50 years; solid bars  age
50 years.
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prevalence of aortic stenosis also increased with the increas-
ing latency period (Table 2). After adjusting for age and
gender, the odds of having aortic stenosis increased 13.9-
fold (95% CI 12.2 to 15.8) for each 10-year increase in
latency period.
Older age and female gender were associated (p  0.05)
with greater aortic valve regurgitation, but not with mitral,
tricuspid, or pulmonic regurgitation after adjustment for the
latency period. No patient40 years and a latency period of
10 years or less had mild or greater aortic regurgitation
(Fig. 1). In contrast, 71% (17/24) patients 50 years with a
latency period 20 years had at least mild aortic regurgita-
tion. After adjustment for age and latency period, women
had 2.1 (95% CI 1.5 to 3.0)-fold greater odds of having
aortic regurgitation than men.
Calcification of the aortic-mitral intervalvular fibrosa.
There was an unusually marked calcification of the inter-
valvular fibrosa of the aortic valve and the anterior mitral
valve leaflet in 26% (76/294) patients. This calcification
was isolated (without associated aortic or mitral valve
thickening) in 8% (23/294). Calcification of the aortic valve,
mitral valve, or the intervalvular fibrosa was present in
90% (66/73) of patients treated 20 years earlier, compared
with 39% (14/36) for those treated within five years of
echocardiography.
Auscultation and valvular disease. Aortic regurgitation
was rarely suspected on the basis of the physical examination
of the patient’s attending physician (noncardiologist). Of 64
patients potentially at risk for endocarditis from aortic
regurgitation (mild or greater) undergoing auscultation, a
diastolic murmur was detected in only four patients (6.3%).
Systolic murmurs were heard in 71 (29%) of the 243
patients that underwent auscultation. Of 11 patients with
moderate or greater mitral or tricuspid regurgitation, a
systolic murmur was heard in eight patients (73%), com-
pared with 62 of 232 (27%) patients with less or no
regurgitation (p  0.002). Overall the systolic murmur had
a sensitivity of 80% (16/20) but a limited specificity of 77%
(168/223) with a positive predictive value of only 23%
(16/71) for detecting significant valve disease that is typi-
cally associated with a systolic murmur (aortic stenosis,
moderate mitral, or moderate tricuspid regurgitation).
LV disease. M-mode tracings were adequate for measure-
ment of LV dimensions in 263 (89%) patients (Table 3).
Depressed fractional shortening (30%) was more frequent
in patients following irradiation (36%) than in a Framing-
ham cohort without a history of MI (3%, p  0.01) (20). In
multivariate analyses only age was independently associated
with fractional shortening (absolute 0.15% increase in frac-
tional shortening per year, p  0.0001).
Regional wall motion abnormalities were also more com-
mon in our cohort than in the Framingham population.
Compared to the 5% prevalence in Framingham, the prev-
alence of wall motion abnormalities was 13% (12/89) for
those with a latency period of two to 10 years, 18% (24/132)
for a latency period of 11 to 20 years, and 29% (21/73) for
a latency period more than 20 years (p  0.04 for difference
between latency groups). Only one segment in one patient
was considered akinetic. There were no dyskinetic segments
identified. In multivariate analyses regional wall motion
abnormalities were independently related to a greater bio-
logically equivalent dose (odds ratio 1.07 per one-unit
increase, 95% CI 1.02 to 1.13), and older age (odds ratio 1.7
per 10-year increase, 95% CI 1.2 to 2.4) in addition to time
following irradiation.
LV mass. Left ventricular mass was lower for irradiated
patients than for the Framingham population (Table 3).
Left ventricular hypertrophy (defined as more than 163 g/m
for men and 121 g/m for women) was present in 6% (7/121)
of female and 2% (2/104) of male patients compared with
19% of women and 16% of men in the Framingham Heart
Study (21). The difference in mass was due to smaller LV
diastolic volume in patients following irradiation, as systolic
volume and wall thickness were similar to the Framingham
cohort.
We found that ventricular mass adjusted for height
remained constant or decreased slightly over time following
irradiation. This is opposite to the usual increase in LV mass
that occurs with aging (22). Although mass was not clearly
related to the latency period in univariate analysis (Table 3),
when we stratified by age a clear trend toward lower mass
with greater latency period was observed (Fig. 2). In
multivariate analysis that controlled for gender, ventricular
mass decreased by 0.6 g/m (p  0.001) for each year
Table 3. LV Size and Function Following Irradiation
LV Measurement
Years Following Irradiation
p Value†
General Population*
All Patients
(n  263)
2–10
(n  84)
11–20
(n  120)
>20
(n  59) Values Reference
Fractional shortening (%) 31  6 32  5 31  5 31  6 0.74 36  4 (25)
Fractional shortening  30% (%) 95 (36) 32 (38) 39 (33) 24 (41) 0.51 3 (18)
Mass/height (g/m)‡ 90  27 93  26 89  26 91  30 0.59 117 (19)
Wall thickness (posterior  septal, cm) 1.9  0.3 1.9  0.3 1.9  0.3 1.9  0.4 0.88 1.9  0.2 (25)
End diastolic dimension (cm) 4.6  0.5 4.7  0.5 4.6  0.5 4.5  0.5 0.24 5.1  0.4 (25)
End systolic dimension (cm) 3.2  0.4 3.2  0.5 3.2  0.4 3.1  0.5 0.71 3.3  0.3 (25)
*Framingham data; †p for differences across groups based on time following irradiation; ‡LV mass/height available for 225 patients (latency 2–10 years, 78; latency 11–20 years,
111; latency 20 years, 36).
LV  left ventricular.
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following irradiation, but increased by 0.8 g/m (p 0.0001)
for each year increase of age. Similar findings were observed
for combined septal and posterior wall thickness, which
decreased by 0.05 mm (p  0.08) for each year following
irradiation, but increased by 0.1 mm (p  0.001) for each
year increase in age.
Pericardial disease. Pericardial thickening was present in
21% (62/294) of patients compared with a Framingham
prevalence of 2.5% (23). Pericardial effusions (all small)
were noted in 10 (3%). Pericardial thickening was slightly
more common in patients with long latency periods with a
prevalence of 16% (14/89) for the 2 to 10 year latency group,
18% (24/132) for the 11 to 20 year latency group, and 33%
(24/73) for the 20-year latency group (p  0.02). No
patient had wall-motion abnormalities or Doppler findings
suggestive of constrictive pericarditis (25% variation in
E velocity with respiration and deceleration time 160 ms or
less).
Electrocardiographic findings. Electrocardiography (98%
had adequate tracings) was rarely abnormal, and prevalence
rates were similar to Framingham reports (24–27) (Table
4). The prevalence of LV hypertrophy, right bundle branch
block, and abnormal Q-waves increased with increasing
time following irradiation. Resting heart rate also was
higher in patients with longer latency periods (70  13
beats/min for 10 years, 74  12 for 11 to 20 years, and
81  10 for 20 years, p  0.0001). In multivariate
analyses controlling for age, gender, diabetes, hypertension,
and dose of irradiation, a 10-year increase in latency period
was independently predictive of a higher resting heart rate
(increase 3.7 beats/min, 95% CI 1.3 to 6.1), right bundle
branch block (odds ratio 7.3, 95% CI 1.2 to 45), and
abnormal Q-waves (odds ratio 4.9, 95% CI 1.7 to 14).
Follow-up. During 3.2  1.3 years of follow-up nine
patients died (one MI, four malignancy, two pulmonary
disease, one renal failure, one unknown). Another 16
patients developed new cardiac disease (five angina or
revascularization, five nonfatal MI, three HF, two constric-
tive pericarditis, one syncope). Event-free survival was
strongly associated with time from irradiation to echocar-
diography (Fig. 3). Using a proportional hazards model that
controlled for age, gender, radiation dose, patient charac-
teristics, and echocardiographic findings, only the latency
period (time from irradiation to echocardiography) was
independently associated with worse event-free survival
(hazard ratio 3.6 per 10-year increase in latency period, 95%
CI 1.8 to 7.4).
Figure 2. Mean left ventricular mass adjusted for body height and stratified
by age and time following irradiation. As previously described for the
general population, left ventricular mass increases with age. However, for
any age group, mass decreases as time following irradiation increases. Open
bars  age 40 years; lined bars  age 40 to 50 years; solid bars  age
50 years.
Table 4. Electrocardiogram Findings Following Irradiation
Electrocardiographic Finding
Years Following Irradiation
p Value†
General Population*
All Patients
n  288
2–10
n  87
11–20
n  130
>20
n  71 Values (%) Reference
1st degree AV block (%) 2 (0.7) 1 (1) 1 (0.8) 0 (0) 0.68 1.4 (34)
Right bundle branch block (%) 8 (3) 0 (0) 2 (2) 6 (8) 0.003 0.7 (35)
Left bundle branch block (%) 1 (0.4) 0 (0) 0 (0) 1 (1) 0.25 0.3 (35)
LV hypertrophy (%) 6 (2) 0 (0) 2 (2) 4 (6) 0.03 1.9 (36)
Abnormal Q waves (%) 11 (4) 0 (0) 4 (3) 7 (10) 0.005 1.4 (34)
ST or T-wave abnormalities (%) 15 (5) 4 (5) 6 (5) 5 (7) 0.74 4 (37)
*Population data from Framingham, Massachusetts or Tecumseh, Michigan; †p for differences across groups based on time following irradiation.
AV  atrioventricular; LV  left ventricular.
Figure 3. Survival free from cardiac events (death, heart failure, symptom-
atic coronary artery disease, valve replacement) is displayed for patients
grouped by time following irradiation. The event rate increases with
increasing time following irradiation, which persists after adjustment for
age, gender, and radiation dose. Solid line  2 to 10 years; line with
circles  11 to 20 years; dashed line  20 years.
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DISCUSSION
This study documented frequent abnormalities in valvular
function, LV mass, and systolic function in asymptomatic
patients that had previously received mediastinal irradiation.
The prevalence of cardiac disease was several-fold higher
than in the Framingham population and increased with
time following irradiation. Previous studies have shown that
symptomatic disease occurs in approximately 5% of patients
by 10 years following treatment for Hodgkin’s disease
(28,29). The results of this study show that by 20 years the
majority of asymptomatic patients have valvular disease for
which endocarditis prophylaxis has been recommended.
Abnormalities of the aortic valve were more common
than abnormalities of the mitral and tricuspid valves al-
though all were more frequently incompetent than in the
Framingham population. The increased frequency of aortic
valve pathology is likely due to the proximity of the aortic
valve to the mediastinal radiation field. By 20 years follow-
ing irradiation few patients had a normally functioning
aortic valve.
An important result from this study is that many irradi-
ation induced abnormalities become more frequent over
time, a finding that was independent of age. Irradiation
appears to initiate a degenerative process that continues for
at least the next 20 years. Thus, the absence of valvular
disease early after irradiation does not indicate a low risk for
valvular disease in the future.
Our study observed a progressive decrease in LV mass,
diastolic cavity dimensions, and wall thickness following
irradiation after adjustment for age. Although radiation-
induced atrophy of noncardiac muscle has been documented
(30), the finding of decreasing LV mass with time following
irradiation has not been previously reported and is opposite
to the normal increase with age (22). Left ventricular
systolic dimensions were similar to the Framingham popu-
lation (31) resulting in a mildly reduced fractional shorten-
ing in the irradiated patients. The clinical implications of
reduced LV mass and fractional shortening are unclear and
further follow-up is needed to determine if these patients
are at increased risk for HF or other cardiac disease.
Comparison with previous studies. Several prior studies
have evaluated patients with Hodgkin’s following irradia-
tion with two-dimensional (28,29,32) or M-mode echocar-
diography (33). These studies included symptomatic pat-
ents, were smaller than the present investigation (sample
size range 25 to 116), and had a shorter time from treatment
to evaluation (range 5 to 11 years) compared with our study.
Our study is consistent with these reports in noting a high
prevalence of aortic valvular disease. Our finding of de-
creased cavity size and reduced LV systolic function follow-
ing irradiation confirms the findings of an early study (33)
but contradicts a more recent investigation (34) showing no
effect of irradiation on systolic function.
Clinical implications. Our study has several clinical impli-
cations. Endocarditis prophylaxis would be recommended
for 29% of patients using the criteria from the Food and
Drug Administration (7). Screening with echocardiography
may thus be beneficial, particularly in those that have
survived 10 years following irradiation, where one in four
patients are candidates for endocarditis prophylaxis. The
physical exam (by the attending radiation or medical oncol-
ogist) provided limited information, with a positive predic-
tive value of 25% for a systolic murmur to detect aortic
stenosis, moderate mitral or tricuspid regurgitation, and a
sensitivity of 5% for a diastolic murmur to detect mild or
greater aortic regurgitation. Pending a cost-effectiveness
analysis, it appears reasonable to perform at least one
screening echocardiogram in patients who have survived 10
years following mediastinal irradiation (35 Gy or more).
Study limitations. This study has several limitations. Irra-
diation treatment has changed over the past 30 years with a
gradual decrease in the total dose used. Previously, patients
received more than 40 Gy regardless of the use of chemo-
therapy. During the past 10 to 15 years patients treated with
radiation alone frequently receive 44 Gy, whereas those
treated with eight weeks of chemotherapy may receive
30 Gy if they have early disease. The average follow-up after
echocardiography was less than four years in our study.
Therefore, the rate of progression from asymptomatic to
symptomatic disease is unclear. Our study was limited to
patients with a prior history of Hodgkin’s disease. However,
other studies have documented an increased risk of cardiac
disease following radiation treatment for testicular (35) and
breast cancer (36).
Conclusions. In summary, our study found a high preva-
lence of cardiac abnormalities in asymptomatic patients
following mediastinal irradiation. In particular, aortic valve
disease, reduced LV systolic function, and pericardial dis-
ease were noted more frequently in our irradiated cohort
than in the Framingham population. In contrast, LV mass
was reduced compared to Framingham subjects. The latency
period following irradiation was the most important risk
factor for development of valvular and conduction disease
abnormalities and was independent of age. These findings
suggest that echocardiography should be considered during
follow-up care for asymptomatic patients who have received
more than 35 Gy of mediastinal irradiation.
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